Association analysis of SIGMAR1 with major depressive disorder and SSRI response

Neuropharmacology

Volumn 58, Issue 7, 2010, Pages 1168-1173

  Kishi, Taro ^a   Yoshimura, Reiji ^b   Okochi, Tomo ^a   Fukuo, Yasuhisa ^a   Kitajima, Tsuyoshi ^a   Okumura, Takenori ^a   Tsunoka, Tomoko ^a   Kawashima, Kunihiro ^a   Yamanouchi, Yoshio ^a   Kinoshita, Yoko ^a   Umene Nakano, Wakako ^b   Naitoh, Hiroshi ^a   Nakamura, Jun ^b   Ozaki, Norio ^c   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Functional SNP; Linkage disequilibrium; Major depressive disorder; Sigma1 non opioid intracellular receptor 1 gene (SIGMAR1); SSRIs response

Indexed keywords

ALPRAZOLAM; BROMAZEPAM; ESTAZOLAM; ETIZOLAM; FLUNITRAZEPAM; LOFLAZEPATE; QUAZEPAM; SEROTONIN UPTAKE INHIBITOR; SIGMA 1 OPIATE RECEPTOR; TRIAZOLAM; ZOLPIDEM;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INTERVIEW; JAPANESE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PHENOTYPE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; REMISSION; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUVOXAMINE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, SIGMA; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77950935011     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.02.013     Document Type: Article

References (51)

1. Akunne H.C., Whetzel S.Z., Wiley J.N., Corbin A.E., Ninteman F.W., Tecle H., Pei Y., Pugsley T.A., Heffner T.G. The pharmacology of the novel and selective sigma ligand, PD 144418. Neuropharmacology 1997, 36:51-62.
2. Ansorge M.S., Hen R., Gingrich J.A. Neurodevelopmental origins of depressive disorders. Curr. Opin. Pharmacol. 2007, 7:8-17.
3. Ault D.T., Werling L.L. Phencyclidine and dizocilpine modulate dopamine release from rat nucleus accumbens via sigma receptors. Eur. J. Pharmacol. 1999, 386:145-153.
4. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
5. Bermack J.E., Debonnel G. Modulation of serotonergic neurotransmission by short- and long-term treatments with sigma ligands. Br. J. Pharmacol. 2001, 134:691-699.
6. Bermack J.E., Debonnel G. The role of sigma receptors in depression. J. Pharmacol. Sci. 2005, 97:317-336.
7. 3H]1,3-di(2-tolyl)guanidine and [3H](+)pentazocine binding sites in the rat brain: autoradiographic visualization of the putative sigma1 and sigma2 receptor subtypes. Neuroscience 1997, 76:467-477.
8. Bowden C.L. Strategies to reduce misdiagnosis of bipolar depression. Psychiatr. Serv. 2001, 52:51-55.
9. Chakravarti A. Population genetics-making sense out of sequence. Nat. Genet. 1999, 21:56-60.
10. Garriock H.A., Kraft J.B., Shyn S.I., Peters E.J., Yokoyama J.S., Jenkins G.D., Reinalda M.S., Slager S.L., McGrath P.J., Hamilton S.P. A genomewide association study of citalopram response in major depressive disorder. Biol. Psychiatry 2010, 67:133-138.
11. Gonzalez-Alvear G.M., Thompson-Montgomery D., Deben S.E., Werling L.L. Functional and binding properties of sigma receptors in rat cerebellum. J. Neurochem. 1995, 65:2509-2516.
12. Gronier B., Debonnel G. Involvement of sigma receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems. Eur. J. Pharmacol. 1999, 368:183-196.
13. Hashimoto K., Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr. Pharm. Des. 2006, 12:3857-3876.
14. Hayashi T., Su T.P. An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma 1 receptor ligand. Expert. Opin. Ther. Targets 2008, 12:45-58.
15. Inada T., Iijima Y., Uchida N., Maeda T., Iwashita S., Ozaki N., Harano M., Komiyama T., Yamada M., Sekine Y., Iyo M., Sora I., Ujikec H. No association found between the type 1 sigma receptor gene polymorphisms and methamphetamine abuse in the Japanese population: a collaborative study by the Japanese genetics initiative for drug abuse. Ann. N.Y. Acad. Sci. 2004, 1025:27-33.
16. Ishiguro H., Ohtsuki T., Toru M., Itokawa M., Aoki J., Shibuya H., Kurumaji A., Okubo Y., Iwawaki A., Ota K., Shimizu H., Hamaguchi H., Arinami T. Association between polymorphisms in the type 1 sigma receptor gene and schizophrenia. Neurosci. Lett. 1998, 257:45-48.
17. Ishikawa M., Ishiwata K., Ishii K., Kimura Y., Sakata M., Naganawa M., Oda K., Miyatake R., Fujisaki M., Shimizu E., Shirayama Y., Iyo M., Hashimoto K. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol. Psychiatry 2007, 62:878-883.
18. Kamei H., Kameyama T., Nabeshima T. Effects of sigma receptor ligands on conditioned fear stress. Methods Find. Exp. Clin. Pharmacol. 1998, 20:613-618.
19. Kishi T., Kitajima T., Ikeda M., Yamanouchi Y., Kinoshita Y., Kawashima K., Okochi T., Okumura T., Tsunoka T., Inada T., Ozaki N., Iwata N. Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259:293-297.
20. Kishi T., Kitajima T., Ikeda M., Yamanouchi Y., Kinoshita Y., Kawashima K., Okochi T., Okumura T., Tsunoka T., Ozaki N., Iwata N. CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients. Neuromolecular Med. 2009, 11:53-57.
21. Kishi T., Kitajima T., Ikeda M., Yamanouchi Y., Kinoshita Y., Kawashima K., Okochi T., Ozaki N., Iwata N. Association analysis of nuclear receptor Rev-erb alpha gene (NR1D1) with mood disorders in the Japanese population. Neurosci. Res. 2008, 62:211-215.
22. Kishi T., Kitajima T., Tsunoka T., Ikeda M., Yamanouchi Y., Kinoshita Y., Kawashima K., Okochi T., Okumura T., Inada T., Ozaki N., Iwata N. Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. Neurosci. Res. 2009, 64:231-234.
23. Kishi T., Kitajima T., Tsunoka T., Okumura T., Ikeda M., Okochi T., Kinoshita Y., Kawashima K., Yamanouchi Y., Ozaki N., Iwata N. Possible association of prokineticin 2 receptor gene (PROKR2) with mood disorders in the Japanese population. Neuromolecular Med. 2009, 11:114-122.
24. Kronmuller K.T., Schroder J., Kohler S., Gotz B., Victor D., Unger J., Giesel F., Magnotta V., Mundt C., Essig M., Pantel J. Hippocampal volume in first episode and recurrent depression. Psychiatry Res. 2009, 174:62-66.
25. Kulkarni S.K., Dhir A. Sigma-1 receptors in major depression and anxiety. Expert Rev. Neurother. 2009, 9:1021-1034.
26. Laje G., Allen A.S., Akula N., Manji H., John Rush A., McMahon F.J. Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet. Genomics 2009, 19:666-674.
27. Lambert M.T., Trutia C., Petty F. Extrapyramidal adverse effects associated with sertraline. Prog. Neuropsychopharmacol. Biol. Psychiatry 1998, 22:741-748.
28. Maurice T., Phan V.L., Urani A., Kamei H., Noda Y., Nabeshima T. Neuroactive neurosteroids as endogenous effectors for the sigma1 (sigma1) receptor: pharmacological evidence and therapeutic opportunities. Jpn. J. Pharmacol. 1999, 81:125-155.
29. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
30. Miyatake R., Furukawa A., Matsushita S., Higuchi S., Suwaki H. Functional polymorphisms in the sigma1 receptor gene associated with alcoholism. Biol. Psychiatry 2004, 55:85-90.
31. Muglia P., Tozzi F., Galwey N.W., Francks C., Upmanyu R., Kong X.Q., Antoniades A., Domenici E., Perry J., Rothen S., Vandeleur C.L., Mooser V., Waeber G., Vollenweider P., Preisig M., Lucae S., Muller-Myhsok B., Holsboer F., Middleton L.T., Roses A.D. Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. Mol. Psychiatry 2008.
32. Narita N., Hashimoto K., Tomitaka S., Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur. J. Pharmacol. 1996, 307:117-119.
33. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 2006, 59:1151-1159.
34. Nishimura T., Ishima T., Iyo M., Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One 2008, 3:e2558.
35. Ohmori O., Shinkai T., Suzuki T., Okano C., Kojima H., Terao T., Nakamura J. Polymorphisms of the sigma(1) receptor gene in schizophrenia: an association study. Am. J. Med. Genet. 2000, 96:118-122.
36. Peveler R., Kendrick T. Selective serotonin reuptake inhibitors: THREAD trial may show way forward. BMJ 2005, 330:420-421.
37. Prasad P.D., Li H.W., Fei Y.J., Ganapathy M.E., Fujita T., Plumley L.H., Yang-Feng T.L., Leibach F.H., Ganapathy V. Exon-intron structure, analysis of promoter region, and chromosomal localization of the human type 1 sigma receptor gene. J. Neurochem. 1998, 70:443-451.
38. Purcell S., Cherny S.S., Sham P.C. Genetic Power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003, 19:149-150.
39. Sabino V., Cottone P., Parylak S.L., Steardo L., Zorrilla E.P. Sigma-1 receptor knockout mice display a depressive-like phenotype. Behav. Brain Res. 2009, 198:472-476.
40. Saito S., Takahashi N., Ishihara R., Ikeda M., Suzuki T., Kitajima T., Yamanouchi Y., Iwata N., Yamada M., Yoshida K., Inada T., Ozaki N. Association study between vesicle-associated membrane protein 2 gene polymorphisms and fluvoxamine response in Japanese major depressive patients. Neuropsychobiology 2006, 54:226-230.
41. Satoh F., Miyatake R., Furukawa A., Suwaki H. Lack of association between sigma receptor gene variants and schizophrenia. Psychiatry Clin. Neurosci. 2004, 58:359-363.
42. Seth P., Leibach F.H., Ganapathy V. Cloning and structural analysis of the cDNA and the gene encoding the murine type 1 sigma receptor. Biochem. Biophys. Res. Commun. 1997, 241:535-540.
43. Sullivan P.F., de Geus E.J., Willemsen G., James M.R., Smit J.H., Zandbelt T., Arolt V., Baune B.T., Blackwood D., Cichon S., Coventry W.L., Domschke K., Farmer A., Fava M., Gordon S.D., He Q., Heath A.C., Heutink P., Holsboer F., Hoogendijk W.J., Hottenga J.J., Hu Y., Kohli M., Lin D., Lucae S., Macintyre D.J., Maier W., McGhee K.A., McGuffin P., Montgomery G.W., Muir W.J., Nolen W.A., Nothen M.M., Perlis R.H., Pirlo K., Posthuma D., Rietschel M., Rizzu P., Schosser A., Smit A.B., Smoller J.W., Tzeng J.Y., van Dyck R., Verhage M., Zitman F.G., Martin N.G., Wray N.R., Boomsma D.I., Penninx B.W. Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol. Psychiatry 2009, 14:359-375.
44. Suzuki T., Iwata N., Kitamura Y., Kitajima T., Yamanouchi Y., Ikeda M., Nishiyama T., Kamatani N., Ozaki N. Association of a haplotype in the serotonin 5-HT4 receptor gene (HTR4) with Japanese schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 121B:7-13.
45. Uchida N., Ujike H., Nakata K., Takaki M., Nomura A., Katsu T., Tanaka Y., Imamura T., Sakai A., Kuroda S. No association between the sigma receptor type 1 gene and schizophrenia: results of analysis and meta-analysis of case-control studies. BMC Psychiatry 2003, 3:13.
46. Uchida N., Ujike H., Tanaka Y., Sakai A., Yamamoto M., Fujisawa Y., Kanzaki A., Kuroda S. A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer disease. Am. J. Geriatr. Psychiatry 2005, 13:1062-1066.
47. Wang L., Duncan G. Silencing of sigma-1 receptor induces cell death in human lens cells. Exp. Cell Res. 2006, 312:1439-1446.
48. 3H] dopamine release from mesolimbic and mesocortical areas of guinea pig brain by sigma receptors. Schizophr. Res. 1996, 21:51-62.
49. Williams J.B. A structured interview guide for the Hamilton Depression Rating Scale. Arch. Gen. Psychiatry 1988, 45:742-747.
50. Yamaguchi-Kabata Y., Nakazono K., Takahashi A., Saito S., Hosono N., Kubo M., Nakamura Y., Kamatani N. Japanese population structure, based on SNP genotypes from 7003 individuals compared to other ethnic groups: effects on population-based association studies. Am. J. Hum. Genet. 2008, 83:445-456.
51. Yamazaki Y., Ishioka M., Matsubayashi H., Amano T., Sasa M. Inhibition by sigma receptor ligand, MS-377, of N-methyl-d-aspartate-induced currents in dopamine neurons of the rat ventral tegmental area. Psychopharmacology (Berl.) 2002, 161:64-69.